Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00118768 | A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C | PHASE2 | COMPLETED | 175 | — | — | Aug 1, 2005 | - | Mar 2, 2009 | 19 | United States |
| NCT00120861 | Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy | PHASE2 | COMPLETED | - | — | — | Jan 1, 2005 | - | Jun 10, 2010 | 11 | United States |
| NCT00120835 | Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C | PHASE1 | COMPLETED | - | — | — | Jul 1, 2004 | - | Jun 10, 2010 | 3 | United States, Puerto Rico |
| Name | Type | Description |
|---|---|---|
| valopicitabine | DRUG | - |
| Pegylated Interferon Alfa | DRUG | - |
| pegylated interferon | DRUG | - |
| ribavirin | DRUG | - |
Inclusion Criteria: * Documented clinical history of genotype-1 chronic Hepatitis C and compensated liver disease * Treatment Naive (patient has received no previous treatment for chronic hepatitis C infection) * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Patient i...